STOCK TITAN
  1. Home
  2. News
  3. GRTS

Gritstone bio, Inc. - GRTS STOCK NEWS

Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.

Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:

• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations

Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.

News

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

Rhea-AI Summary
Gritstone bio to present results from Phase 1 studies of its COVID-19 vaccine candidates at IDWeek 2023. Contract with BARDA secured for Phase 2b study. Positive evidence of durable immune responses in South African population. Preliminary results show durable immune response in adults previously vaccinated with mRNA or AZD1222. Interim report of safety, reactogenicity, and immunogenicity of booster vaccine in healthy adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
clinical trial covid-19
-
News

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

Rhea-AI Summary
Gritstone bio awarded $433 million contract by BARDA for Phase 2b study of self-amplifying mRNA vaccine against COVID-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.09%
Tags
clinical trial covid-19
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio granted an employee nonqualified stock options to purchase 14,000 shares of common stock at $1.71 per share. The options will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
News

Gritstone bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Gritstone bio, Inc. announces participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Gritstone bio, Inc. has granted two employees nonqualified stock options to purchase 32,500 shares of its common stock. The exercise price is $1.70, equal to the closing price on August 7, 2023. The stock options will vest over a four-year period, with 25% vesting on the first anniversary of hire and 1/48th vesting monthly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News

Gritstone bio and Genevant Sciences Announce Option and License Agreement

Rhea-AI Summary
Gritstone bio and Genevant Sciences have announced an agreement for Gritstone to have a non-exclusive license under Genevant's LNP technology to develop and commercialize self-amplifying RNA vaccines. The agreement follows successful prior collaborations between the two companies and aims to capitalize on the emergence of RNA vaccines in addressing infectious diseases. Genevant is eligible to receive option maintenance and exercise fees, milestone payments up to $136 million per product, and royalties on future product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
News

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
earnings
-
News

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) has joined the ctMoniTR Project, a research initiative focused on using circulating tumor DNA (ctDNA) as an early indicator of long-term clinical benefit from cancer therapeutics. The project, led by Friends of Cancer Research, aims to provide data-driven evidence on how ctDNA can inform treatment decisions, support drug development, and inform regulatory decision-making. Gritstone and other partners will contribute data to help develop this evidence, with more than 25 studies and 3,000 cancer patients already involved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
partnership
-
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
Stock GRTS logo
Gritstone bio, Inc.

Nasdaq:GRTS

GRTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GRTS Stock Data

3.80M
118.11M
1.91%
29.03%
6.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE